Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1979 1
1980 2
1981 1
1982 5
1983 3
1985 10
1986 11
1987 6
1988 9
1989 6
1990 5
1992 5
1993 2
1994 2
1995 4
1996 1
1997 4
1998 6
1999 3
2000 1
2001 4
2002 4
2003 2
2004 3
2005 4
2006 4
2007 5
2008 3
2009 4
2010 7
2011 11
2012 12
2013 3
2014 4
2015 7
2016 8
2017 2
2018 5
2019 4
2020 2
2021 2
2022 3
2024 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

183 results

Results by year

Filters applied: . Clear all
Page 1
Galectins and Ovarian Cancer.
Shimada C, Xu R, Al-Alem L, Stasenko M, Spriggs DR, Rueda BR. Shimada C, et al. Among authors: spriggs dr. Cancers (Basel). 2020 May 31;12(6):1421. doi: 10.3390/cancers12061421. Cancers (Basel). 2020. PMID: 32486344 Free PMC article. Review.
Progress in BRCA-Mutated Ovarian Cancer.
Spriggs DR, Longo DL. Spriggs DR, et al. N Engl J Med. 2018 Dec 27;379(26):2567-2568. doi: 10.1056/NEJMe1812644. N Engl J Med. 2018. PMID: 30586521 No abstract available.
PARP Inhibitors in Ovarian Cancer Treatment.
Spriggs DR, Longo DL. Spriggs DR, et al. N Engl J Med. 2016 Dec 1;375(22):2197-2198. doi: 10.1056/NEJMe1612843. N Engl J Med. 2016. PMID: 27959768 No abstract available.
Ovarian Cancer Treatment - Are We Getting Warmer?
Spriggs DR, Zivanovic O. Spriggs DR, et al. N Engl J Med. 2018 Jan 18;378(3):293-294. doi: 10.1056/NEJMe1714556. N Engl J Med. 2018. PMID: 29342385 No abstract available.
Antibody-Peptide Epitope Conjugates for Personalized Cancer Therapy.
Zhang S, Yan C, Millar DG, Yang Q, Heather JM, Langenbucher A, Morton LT, Sepulveda S, Alpert E, Whelton LR, Zarrella DT, Guo M, Minogue E, Lawrence MS, Rueda BR, Spriggs DR, Lu W, Langenau DM, Cobbold M. Zhang S, et al. Among authors: spriggs dr. Cancer Res. 2022 Mar 1;82(5):773-784. doi: 10.1158/0008-5472.CAN-21-2200. Cancer Res. 2022. PMID: 34965933
New drugs for ovarian cancer.
Bell-McGuinn K, Konner J, Tew W, Spriggs DR. Bell-McGuinn K, et al. Among authors: spriggs dr. Ann Oncol. 2011 Dec;22 Suppl 8:viii77-viii82. doi: 10.1093/annonc/mdr531. Ann Oncol. 2011. PMID: 22180408 Free article. Review. No abstract available.
Epothilones: better or more of the same?
Sabbatini P, Spriggs DR. Sabbatini P, et al. Among authors: spriggs dr. J Clin Oncol. 2009 Jul 1;27(19):3079-81. doi: 10.1200/JCO.2008.21.6481. Epub 2009 May 18. J Clin Oncol. 2009. PMID: 19451426 Review. No abstract available.
Targeting Galectin 3 illuminates its contributions to the pathology of uterine serous carcinoma.
Matoba Y, Zarrella DT, Pooladanda V, Azimi Mohammadabadi M, Kim E, Kumar S, Xu M, Qin X, Ray LJ, Devins KM, Kumar R, Kononenko A, Eisenhauer E, Veillard IE, Yamagami W, Hill SJ, Sarosiek KA, Yeku OO, Spriggs DR, Rueda BR. Matoba Y, et al. Among authors: spriggs dr. Br J Cancer. 2024 May;130(9):1463-1476. doi: 10.1038/s41416-024-02621-x. Epub 2024 Mar 4. Br J Cancer. 2024. PMID: 38438589 Free PMC article.
Sialyl-Tn serves as a potential therapeutic target for ovarian cancer.
Al-Alem L, Prendergast JM, Clark J, Zarrella B, Zarrella DT, Hill SJ, Growdon WB, Pooladanda V, Spriggs DR, Cramer D, Elias KM, Nazer RI, Skates SJ, Behrens J, Dransfield DT, Rueda BR. Al-Alem L, et al. Among authors: spriggs dr. J Ovarian Res. 2024 Apr 2;17(1):71. doi: 10.1186/s13048-024-01397-1. J Ovarian Res. 2024. PMID: 38566237 Free PMC article.
183 results